# A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

> **NCT02517021** · PHASE3 · COMPLETED · sponsor: **Helsinn Healthcare SA** · enrollment: 405 (actual)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting

## Interventions

- **DRUG:** Pro-netupitant/Palonosetron
- **DRUG:** Netupitant/Palonosetron
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02517021
- **Lead sponsor:** Helsinn Healthcare SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2018-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02517021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02517021, "A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02517021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*